Enhancing drug-drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4

被引:2
|
作者
Jiang, Pin [1 ]
Chen, Tao [2 ]
Chu, Lin-Feng [1 ]
Xu, Ren-Peng [1 ]
Gao, Jin-Ting [3 ]
Wang, Li [3 ]
Liu, Qiang [3 ]
Tang, Lily [3 ]
Wan, Hong [1 ]
Li, Ming [4 ]
Ren, Hong-Can [3 ]
机构
[1] Shanghai Medicilon Inc, Dept DMPK, 585 Chuanda Rd, Shanghai 201299, Peoples R China
[2] Shanghai PharmoGo Co Ltd, Shanghai, Peoples R China
[3] GenFleet Therapeut Shanghai Inc, Drug Discovery Dept, 1206 Zhangjiang Rd, Suite A, Shanghai 201203, Peoples R China
[4] Zhengzhou Univ, Dept Cardiovasc Surg, Affiliated Hosp 1, 1 Jianshe Rd, Zhengzhou 450000, Peoples R China
关键词
Drug-drug interaction; PBPK; fraction metabolized; CYP inhibition;
D O I
10.1080/17425255.2023.2263358
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Enhancing the precision of drug-drug interaction (DDI) prediction is essential for improving drug safety and efficacy. The aim is to identify the most effective fraction metabolized by CY3A4 (fm) for improving DDI prediction using physiologically based pharmacokinetic (PBPK) models.Research Design and Methods: The fm values were determined for 33 approved drugs using a human liver microsome for in vitro measurements and the ADMET Predictor software for in silico predictions. Subsequently, these fm values were integrated into PBPK models using the GastroPlus platform. The PBPK models, combined with a ketoconazole model, were utilized to predict AUCR (AUCcombo with ketoconazole/AUCdosing alone), and the accuracy of these predictions was evaluated by comparison with observed AUCR.Results: The integration of in vitro fm method demonstrates superior performance compared to the in silico fm method and fm of 100% method. Under the Guest-limits criteria, the integration of in vitro fm achieves an accuracy of 76%, while the in silico fm and fm of 100% methods achieve accuracies of 67% and 58%, respectively.Conclusions: Our study highlights the importance of in vitro fm data to improve the accuracy of predicting DDIs and demonstrates the promising potential of in silico fm in predicting DDIs.
引用
收藏
页码:721 / 731
页数:11
相关论文
共 50 条
  • [31] When special populations intersect with drug-drug interactions: Application of physiologically-based pharmacokinetic modeling in pregnant populations
    Sychterz, Caroline
    Galetin, Aleksandra
    Taskar, Kunal S.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2021, 42 (04) : 160 - 177
  • [32] Drug-Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model
    Chiang, Manting
    Sychterz, Caroline
    Gaohua, Lu
    Perera, Vidya
    Gretler, Daniel D.
    Florea, Victoria
    Merali, Samira
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (11) : 1275 - 1282
  • [33] Prediction of the Impact of CYP2C19 Polymorphism on Drug-Drug Interaction between Voriconazole and Tacrolimus Using Physiologically- Based Pharmacokinetic Modelling
    Jin, Zhi-Ping
    Yan, Miao
    Li, Si-Ze
    Wang, Bao-Qing
    Xu, Qing
    Wu, Wei
    Li, Xiao-Yu
    Lv, Qian-Zhou
    Xiang, Xiao-Qiang
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 59
  • [34] Physiologically Based Pharmacokinetic Modeling of Fimasartan, Amlodipine, and Hydrochlorothiazide for the Investigation of Drug-Drug Interaction Potentials
    Rhee, Su-jin
    Lee, Hyun A.
    Lee, Soyoung
    Kim, Eunwoo
    Jeon, Inseung
    Song, Im-Sook
    Yu, Kyung-Sang
    PHARMACEUTICAL RESEARCH, 2018, 35 (12)
  • [35] Physiologically Based Pharmacokinetic Modeling of Tofacitinib: Predicting Drug Exposure and Optimizing Dosage in Special Populations and Drug-Drug Interaction Scenarios
    Cao, Zhihai
    Wang, Zilong
    Zhang, Qian
    Zhang, Wei
    Zheng, Liang
    Hu, Wei
    PHARMACEUTICALS, 2025, 18 (03)
  • [36] Drug-Drug Interaction between (S)-Rivaroxaban and Orthopedics Treatment Drugs Mainly Undergoing CYP3A4 Metabolism
    Shi, Jian-Sheng
    Guo, Yang
    LATIN AMERICAN JOURNAL OF PHARMACY, 2015, 34 (03): : 613 - 615
  • [37] Understanding Statin-Roxadustat Drug-Drug-Disease Interaction Using Physiologically-Based Pharmacokinetic Modeling
    Dong, Jin
    Garcia, Luna Prieto
    Huang, Yingbo
    Tang, Weifeng
    Lundahl, Anna
    Elebring, Marie
    Ahlstrom, Christine
    Vildhede, Anna
    Sjogren, Erik
    Nagard, Mats
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (04) : 825 - 835
  • [38] A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib
    Wang, Ziteng
    Xiang, Xiaoqiang
    Liu, Shuaibing
    Tang, Zhijia
    Sun, Hong
    Parvez, Masud
    Ghim, Jong-Lyul
    Shin, Jae-Gook
    Cai, Weimin
    DRUG METABOLISM AND PHARMACOKINETICS, 2021, 39
  • [39] Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron
    Lin, Jian
    Goosen, Theunis C.
    Tse, Susanna
    Yamagami, Hidetomi
    Malhotra, Bimal
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (11) : 1505 - 1518
  • [40] Physiologically based pharmacokinetic modeling of CYP2C8 substrate rosiglitazone and its metabolite to predict metabolic drug-drug interaction
    Gaud, Nilesh
    Gogola, Dawid
    Kowal-Chwast, Anna
    Gabor-Worwa, Ewelina
    Littlewood, Peter
    Brzozka, Krzysztof
    Kus, Kamil
    Walczak, Maria
    DRUG METABOLISM AND PHARMACOKINETICS, 2024, 57